J-M Ferrero

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

T Bachelot, C. Bourgier, Claire Cropet et al. · Cancer Research · 2010 · 61 citations

Breast Oncology, Pharmacotherapy, Endocrine Oncology +16

Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

P. Cottu, Véronique D’Hondt, Sylvain Dureau et al. · Annals of Oncology · 2017 · 52 citations · Full text

Minal Breast Cancer, Breast Oncology, Unicancer-eopal Study +8

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

PA Kaufman, J-M Ferrero, Hugues Bourgeois et al. · Cancer Research · 2010 · 45 citations

Breast Oncology, Human Growth, Immunology +17

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

F-C Bidard, William Jacot, Sylvain Dureau et al. · Cancer Research · 2019 · 32 citations

Breast Oncology, Patient Selection, Cancer Management +18